ProSomnus, Inc. (OSA)
| Market Cap | 98.03M |
| Revenue (ttm) | 22.68M |
| Net Income (ttm) | -11.73M |
| Shares Out | 18.15M |
| EPS (ttm) | 1.99 |
| PE Ratio | 2.71 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,001 |
| Open | 5.15 |
| Previous Close | 5.17 |
| Day's Range | 5.15 - 5.57 |
| 52-Week Range | 4.57 - 11.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 30, 2023 |
About OSA
Prosomnus Sleep Technologies, Inc. designs, manufactures, and markets sleep apnea therapy devices for dentists to treat patients diagnosed with obstructive sleep apnea. The company was incorporated in 2016 and is based in Pleasanton, California. [Read more]
Financial Performance
Financial StatementsNews
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will ...
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society's Sleep and Breathing 2023 Conference
PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announ...
ProSomnus® Appoints Brian Dow as Chief Financial Officer
PLEASANTON, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
Company commences execution of strategic growth initiatives following Initial Public Offering Company commences execution of strategic growth initiatives following Initial Public Offering
ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference
Data from First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study will be presented for the first time Data from First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study will be pre...
ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital's First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)
First prospective crossover study comparing the effectiveness of precision oral appliance therapy as front-line therapy relative to CPAP for the treatment of obstructive sleep apnea
ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device
Additional reimbursement coverage further expands the market for ProSomnus as the Company seeks to make precision oral appliance therapy a first-line treatment for obstructive sleep apnea Additional r...
ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices
SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the complet...